NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors

ABSTRACT: This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.

DISEASE(S): Solid Tumor,Glioma,Colorectal Cancer,Carcinoma, Hepatocellular,Hepatocellular Carcinoma

PROVIDER: 2351696 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR